Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.
News & Analysis: Dicerna Pharmaceuticals
Volatile stock market or not, these two drug developers are well positioned for long-term success.
DRNA earnings call for the period ending March 31, 2020.
These development-stage drug companies are well positioned for success, even amid the current market uncertainty.
DRNA earnings call for the period ending December 31, 2019.
These two promising RNAi drug developers are trading at hefty premiums going into 2020.
What goes up must come down. But today's tumble means relatively little for investors with a long-term mindset.
A $9.7 billion deal and two failed takeover bids ushered in renewed enthusiasm for acquisitions in the pharmaceutical industry. What makes these stocks buyout candidates?
This early-stage biopharma is developing a promising gene-silencing pipeline that's beginning to turn heads.
The small-cap biopharma inked a deal with a major pharmaceutical company, its second in three weeks.